Loading…
No business profile yet.
Size YungShin Global (3705.TW) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $474M, the 464th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$58.80 on 6 Nov 2026.
Performance Over six months the shares gained 6.9%, against -20.6% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue fell 8.4% over the last twelve months (peer median -4.9%); the operating margin is 14.6% (peer median 3.3%).
Valuation It trades at 1.9× enterprise value to sales against a peer median of 3.5× (6th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -6 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.9 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$7.84B | NT$8.38B | NT$8.03B | NT$7.03B | NT$7.31B |
| Revenue growth | — | +4% | +14% | -4% | — |
| Gross profit | NT$3.35B | NT$3.58B | NT$3.46B | NT$2.91B | NT$3.06B |
| EBITDA | NT$1.42B | NT$1.61B | NT$1.59B | NT$1.22B | NT$1.13B |
| Net income | NT$896M | NT$881M | NT$1.17B | NT$827M | NT$839M |
| Free cash flow | NT$895M | NT$1.01B | NT$1.14B | NT$1.09B | NT$820M |
| Capital expenditure | NT$519M | NT$516M | NT$241M | NT$125M | NT$151M |
| Total debt | NT$1.30B | NT$1.19B | NT$1.23B | NT$1.24B | NT$1.83B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3705.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.9% | -11.3% | 2nd highest of 20 |
| 6-month return | +6.9% | -20.6% | 5th highest of 20 |
| Distance from 52-week high | -5.2% | -40.7% | highest of 20 |
| Revenue growth (TTM) | -8.4% | -4.9% | 9th lowest of 21 |
| Operating margin | 14.6% | 3.3% | 2nd highest of 21 |
| EV / Sales | 1.9× | 3.5× | 6th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -4.9% | 7.1% | 3rd least demanding of 12 |
| Growth delivered (Del g) | +0.7% | +1.0% | 6th lowest of 12 |
| Hurdle (Req g minus delivered) | -5.6 pp | +5.8 pp | 2nd least demanding of 12 |
| ROIC minus cost of capital | +6.9 pp | -3.7 pp | highest of 19 |
| EV / EBITDA | 10.4× | n/a | — |
| Net debt / EBITDA | -1.2× | 2.1× | 2nd least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | 1.9× | -4.9% | +0.7% |
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 2.5× | 5.7% | +3.3% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | 11.5× | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $476M | -10% | +40% | 13% | 11.1× | 44.5% | +1.0% |
| Cachet Pharmaceutical 002462.SZ | China | $471M | -22% | -14% | 0% | 0.2× | -8.9% | -3.4% |
| Kexing Biopharm 688136.SS | China | $470M | -38% | -14% | -12% | 3.1× | n/a | n/a |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $470M | -39% | +35% | 4% | 1.2× | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $477M | +62% | +10,947% | -194% | 132.2× | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $477M | -45% | -87% | -477% | 8.3× | n/a | n/a |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $467M | -13% | -5% | -29% | 4.5× | n/a | n/a |
| Evonile Pharma EVONILE.NS | India | $466M | n/a | -5% | 12% | 14.5× | 46.5% | -1.5% |
| Alpha Teknova TKNO | United States | $482M | +104% | +12% | -35% | 11.3× | n/a | n/a |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $466M | -20% | -21% | -68% | 9.0× | n/a | n/a |
| Teyi Pharmaceutical 002728.SZ | China | $465M | -9% | -7% | 7% | 3.5× | 26.6% | +8.0% |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $483M | +9% | -4% | 3% | 1.4× | 13.4% | +1.4% |
| Shanghai Jiaoda Onlly 600530.SS | China | $464M | -22% | -2% | -2% | 10.4× | 33.5% | -0.9% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $464M | -30% | +14% | 5% | 2.4× | 2.5% | -1.3% |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $484M | -23% | -14% | 12% | 0.5× | -18.6% | +6.3% |
| Daewoong 003090.KS | South Korea | $485M | -29% | +5% | 11% | 0.9× | n/a | n/a |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $463M | -21% | +7% | 19% | 3.6× | 7.1% | +1.3% |
| PKU Healthcare 000788.SZ | China | $489M | -11% | -49% | 5% | 2.5× | -2.6% | -5.6% |